Search alternatives:
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
sizes decrease » scores decreased (Expand Search), rivers decreased (Expand Search)
point decrease » point increase (Expand Search)
Showing 1 - 20 results of 7,672 for search '(( significant treatment decrease ) OR ( significant ((sizes decrease) OR (point decrease)) ))', query time: 0.65s Refine Results
  1. 1
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Analysis of Significantly Different Bacteria.

    Analysis of Significantly Different Bacteria. by Xu Jia (187142)

    Published 2025
    Save to List
    Saved in:
  3. 3
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes.

    Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
    Save to List
    Saved in:
  6. 6
    Cephalometric measurement points.

    Cephalometric measurement points. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Summary of five key points guiding the Safe Steps evaluation and implementation.

    Summary of five key points guiding the Safe Steps evaluation and implementation. by Esario IV Daguman (21474116)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Middle cerebral artery mean flow velocity at three time points.

    Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 15
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease.

    Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients.... by Emir Matpan (21655811)

    Published 2025
    “…<p>Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. …”
    Save to List
    Saved in:
  19. 19
    Sediment particle size curve.

    Sediment particle size curve. by Hui Zhang (7197)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 20
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: